Neuland Laboratories Limited CC-Jun25.pdf · 2025-07-31
Hi, sir. Good evening. So, considering the revenue composition, the CMS business contributed around 44% of the revenue in the current quarter. Considering the high -margin business that CMS is, why is the margin fall so very significant in this quarter?
And previously, you had indicated that this financial year, we will see a commercialization of another molecule in addition to a molecule which was already commercialized in the previous year. So, is that guidance to be continued or do you see any other molecule being commercialized in the current quarter?